Form 4: ABEONA CEO Sells Shares Under 10b5-1 Plan

ABEONA THERAPEUTICS INC. CEO Vishwas Seshadri sold 25,000 shares of common stock for approximately $5.31 per share as part of a pre-arranged trading plan.

Summary

• Vishwas Seshadri, Chief Executive Officer and Director of ABEONA THERAPEUTICS INC., sold 25,000 shares of the company's common stock.
• The transaction occurred on December 29, 2025.
• The shares were sold at a weighted average price of $5.3096 per share, with individual transaction prices ranging from $5.215 to $5.41.
• This sale was executed automatically pursuant to a Rule 10b5-1 trading plan that Mr. Seshadri adopted on September 18, 2024.
• Following this transaction, Mr. Seshadri beneficially owns 1,164,818 shares of ABEONA THERAPEUTICS INC. common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which typically has a neutral impact as it is not indicative of new information or a change in company prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct ownership stake of the Chief Executive Officer in the company.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

This filing is a standard regulatory disclosure of an insider stock transaction and does not provide broader industry context or trends.

Related Party Transactions

• Vishwas Seshadri, CEO and Director, sold 25,000 shares of common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The CEO's direct ownership stake is slightly reduced, but the pre-arranged nature of the sale under a 10b5-1 plan mitigates concerns about its implications.

Key Dates

Recommendation

The insider sale by CEO Vishwas Seshadri was conducted under a pre-established Rule 10b5-1 trading plan, which typically signals a planned liquidity event rather than a reaction to new material non-public information. While any insider sale reduces management's direct stake, the pre-arranged nature mitigates concerns about negative sentiment. Without additional information on company performance or strategic shifts, this transaction alone does not warrant a change from a 'hold' position.

Keywords

ABEONA THERAPEUTICS, ABEO, Vishwas Seshadri, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Biotechnology